Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Bowman & Co S.C.

Bowman & Co S.C. trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.1% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 9,934 shares of the medical research company’s stock after selling 322 shares during the period. Bowman & Co S.C.’s holdings in Edwards Lifesciences were worth $949,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $34,000. DSM Capital Partners LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $34,000. Rise Advisors LLC raised its stake in shares of Edwards Lifesciences by 125.0% during the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock worth $46,000 after buying an additional 265 shares during the period. Finally, Pingora Partners LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $91.56 on Thursday. The stock has a market cap of $55.17 billion, a PE ratio of 39.47, a P/E/G ratio of 3.33 and a beta of 1.11. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock has a fifty day simple moving average of $87.50 and a 200-day simple moving average of $84.95.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Mizuho increased their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Citigroup raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $98.00 to $105.00 in a research note on Wednesday, May 22nd. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.06.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,108,777.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $414,596.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,108,777.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,104 shares of company stock worth $11,267,464. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.